comparemela.com

Latest Breaking News On - Hoffmann - Page 5 : comparemela.com

F Hoffmann-La Roche Ltd: Roche s BTK inhibitor fenebrutinib significantly reduced brain lesions in people with relapsing forms of multiple sclerosis

Fenebrutinib is an investigational, potent and highly selective oral Bruton's tyrosine kinase (BTK) inhibitor, the only reversible BTK inhibitor currently in Phase III multiple sclerosis (MS) trialsPhase

F Hoffmann-La Roche Ltd: FDA accepts application for Roche s Vabysmo for the treatment of retinal vein occlusion (RVO)

Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was further

vimarsana © 2020. All Rights Reserved.